By Billy Candra 
Cambridge researchers have unveiled a groundbreaking new treatment approach that has demonstrated a remarkable 100% survival rate over a critical three-year period for patients with aggressive, inherited breast cancers. This pioneering method, which combines chemotherapy with a targeted cancer drug before surgery, marks a significant leap forward in the fight against early-stage breast cancer linked to BRCA1 and BRCA2 gene mutations. The findings, published today in the esteemed journal Nature Communications, suggest this could become the most effective treatment to date for this particularly challenging form of the disease.
Understanding BRCA-Mutated Cancers: A Persistent Challenge
Breast cancers stemming from faulty copies of the BRCA1 and BRCA2 genes are notoriously aggressive and complex to treat. These genes typically act as tumor suppressors, playing a crucial role in repairing damaged DNA and preventing uncontrolled cell growth. When mutations occur in these genes, the body’s ability to repair DNA is compromised, significantly increasing the risk of developing certain cancers, most notably breast and ovarian cancers, but also prostate and pancreatic cancers.
The public became acutely aware of the implications of BRCA gene mutations when actress Angelina Jolie, a carrier of the BRCA1 mutation, underwent a preventative double mastectomy in 2013. Her candid revelation sparked a global conversation about genetic testing, risk assessment, and proactive health management, bringing inherited breast cancer into mainstream consciousness. Despite increased awareness, effective treatment strategies for these aggressive forms of cancer have remained a critical unmet need.
Current standard treatment protocols for early-stage breast cancer, including those with BRCA mutations, typically involve a multi-modal approach. This often begins with neoadjuvant chemotherapy, sometimes combined with immunotherapy, administered before surgery to shrink the tumour. The goal is to make the tumour easier to remove and to eliminate micrometastases, tiny clusters of cancer cells that may have spread beyond the primary site. Following surgery, patients may receive radiation therapy and further systemic treatments. The initial three years post-surgery are considered a critical window, as this is when the risk of relapse or death is highest. For patients with BRCA-mutated cancers, the aggressive nature of these tumours often translates to a higher risk of recurrence during this period, underscoring the urgency for more effective interventions.
The Partner Trial: A Paradigm Shift in Treatment Strategy
The Partner trial, led by researchers from Addenbrooke’s Hospital, part of Cambridge University Hospitals (CUH) NHS Foundation Trust, and the University of Cambridge, adopted a distinctly innovative approach. The study introduced two key advancements: the pre-surgical (neoadjuvant) administration of olaparib, a targeted cancer drug, in conjunction with chemotherapy, and a carefully optimized timing schedule for these treatments.
Olaparib, marketed as Lynparza, is a poly (ADP-ribose) polymerase (PARP) inhibitor. PARP enzymes are involved in DNA repair, and in cells with BRCA mutations, the primary DNA repair pathway is already deficient. By inhibiting PARP, olaparib essentially creates a "synthetic lethality" in cancer cells with BRCA mutations, as they lose their remaining ability to repair DNA, leading to cell death. This targeted therapy has already been approved and is available on the NHS for certain advanced cancers, particularly ovarian and breast cancers with BRCA mutations, typically administered post-surgery or for metastatic disease. The Partner trial explored its efficacy in an earlier, neoadjuvant setting.
Patients for the trial were recruited from 23 NHS sites across the UK, reflecting a broad national collaboration in this vital research. A total of 39 patients received the experimental regimen of chemotherapy followed by olaparib, while 45 patients in the control arm received chemotherapy only, consistent with the standard of care at the time.
The Crucial 48-Hour Gap: Unlocking Enhanced Efficacy
One of the most intriguing and impactful innovations of the Partner trial was the discovery of a critical 48-hour "gap" between the administration of chemotherapy and olaparib. The results clearly demonstrated that allowing this brief pause between treatments led to significantly better outcomes. The scientific rationale behind this timing appears to be twofold: it provides the patient’s bone marrow with crucial time to recover from the myelosuppressive effects of chemotherapy, thereby potentially reducing severe side effects and improving treatment tolerability. Simultaneously, it is hypothesized that this timing maintains the tumour cells’ susceptibility to the targeted action of olaparib, maximizing its therapeutic impact on the BRCA-deficient cancer cells. This strategic sequencing of treatments represents a sophisticated understanding of both drug pharmacology and cancer cell biology.
Stunning Results: A New Benchmark for Survival
The clinical outcomes from the Partner trial were nothing short of remarkable. Of the 39 patients who received the sequential chemotherapy and olaparib treatment, only one patient experienced a relapse three years after surgery. Crucially, 100% of these patients survived the critical three-year post-surgical period. This achievement is particularly significant given the aggressive nature of BRCA-mutated breast cancers and the historical challenges in achieving such high survival rates.
In stark contrast, the control arm, comprising 45 patients who received chemotherapy only, showed a three-year survival rate of 88%. Within this group, nine patients relapsed, and tragically, six of those patients died. The difference in outcomes – a 12 percentage point increase in survival and a dramatically reduced relapse rate – underscores the profound impact of the new treatment approach. These statistics translate into real lives saved and extended, offering immense hope to patients and their families.
A Patient’s Journey: Six Years Cancer-Free
Jackie Van Bochoven, 59, from South Cambridgeshire, stands as a testament to the potential of this innovative treatment. Diagnosed in February 2019 with a small but aggressive tumour, Jackie’s initial reaction was one of profound shock and anxiety. "When I had the diagnosis, I was completely shocked and numb," she recalled. "I thought about my children, and my mum and sister who were diagnosed with breast cancer. I was pretty worried." Her family history of breast cancer amplified her concerns, highlighting the hereditary aspect that drives the urgency for better BRCA-specific treatments.
Enrolled in the Partner trial, Jackie underwent the experimental regimen. Six years on, her life has been transformed. "Six years on, I’m well and cancer free. I’m back at work, enjoying life and spending time with my family," she shared. Her experience encapsulates the ultimate goal of cancer research: not just to treat, but to cure, allowing individuals to reclaim their lives. "When you’ve had cancer, I think you look at life differently and every day is a bonus," Jackie added, her words resonating with the profound impact of surviving such a formidable disease.
Broader Implications and Potential Cost Savings
The implications of the Partner trial extend beyond breast cancer. The findings hold immense potential for application to other cancers driven by faulty copies of BRCA genes, including certain ovarian, prostate, and pancreatic cancers. These cancers also exhibit a reliance on PARP-mediated DNA repair, making them prime candidates for similar targeted therapeutic strategies. If successful, this approach could redefine treatment paradigms for a broader spectrum of inherited cancers.
Furthermore, the new regimen offers potential cost-saving benefits for the NHS, a crucial consideration in healthcare resource management. Currently, patients offered olaparib typically take the drug post-surgery for a period of 12 months. In the Partner trial, patients received the tablets pre-surgery for a significantly shorter duration of just 12 weeks. This reduction in treatment duration, if proven equally effective and safe in larger studies, could lead to substantial cost efficiencies for the healthcare system, freeing up resources while simultaneously improving patient outcomes. Fewer relapses would also mean reduced costs associated with subsequent treatments, hospitalizations, and palliative care.
Expert Perspectives and the Power of Collaboration
Professor Jean Abraham, an Addenbrooke’s consultant and the lead investigator for the Partner trial, expressed profound excitement about the results. "It is rare to have a 100% survival rate in a study like this and for these aggressive types of cancer," she stated. "We’re incredibly excited about the potential of this new approach, as it’s crucial that we find a way to treat and hopefully cure patients who are diagnosed with BRCA1 and BRCA2 related cancers." Professor Abraham, who also holds the title of Professor of Precision Breast Cancer Medicine at the University of Cambridge, highlighted the fortuitous genesis of the 48-hour gap approach, which arose from a "chance conversation" with Mark O’Connor, chief scientist in Early Oncology R&D at nearby AstraZeneca.
Mark O’Connor underscored the broader lessons from the trial: "The Partner trial highlights the importance of detecting and treating cancer early, and the value of innovative science in informing clinical trial design, in this case using bone marrow stem cells to identify the combination gap schedule." He acknowledged the need for further validation in larger studies but reiterated the "incredibly exciting" nature of the findings and their potential to "transform outcomes for patient populations who have unmet clinical need." This emphasis on early detection and innovative trial design underscores a forward-thinking approach to cancer research.
This type of synergistic collaboration between NHS trusts, academia, and industry partners exemplifies the vision driving the development of the Cambridge Cancer Research Hospital. This specialist cancer research hospital, slated to be built on Europe’s leading life sciences campus, the Cambridge Biomedical Campus, aims to consolidate clinical expertise from Addenbrooke’s Hospital with world-class scientists from the University of Cambridge, the Cancer Research UK Cambridge Centre, and industry collaborators. The goal is to foster an environment where new diagnostics and treatments can be rapidly developed to detect the earliest signs of cancer and deliver truly personalised, precision medicine. This integrated approach is increasingly recognized as vital for accelerating medical breakthroughs.
Future Directions and Calls for Further Research
Michelle Mitchell, Chief Executive of Cancer Research UK, lauded the findings, emphasizing the importance of optimizing existing treatments. "One of the best ways that we can beat cancer sooner is by making more effective use of treatments that are already available to us," she commented. While acknowledging that "this research is still in its infancy," she described it as "an exciting discovery that adding olaparib at a carefully-timed stage of treatment can potentially give patients with this specific type of breast cancer more time with their loved ones." Mitchell also stressed the necessity for further studies in more patients to confirm the safety and efficacy of this new technique before it can be widely adopted by the NHS.
Professor Abraham and her team are already laying the groundwork for the next phase of research. This will involve a larger, confirmatory study designed to replicate the promising results observed in the Partner trial. A key focus will be to definitively establish that the Partner approach not only offers superior efficacy but also provides a less toxic treatment regimen for patients, in addition to confirming its cost-effectiveness compared to the current standard of care. This rigorous approach is essential for translating initial breakthroughs into widespread clinical practice.
The Partner trial was a collaborative effort, generously sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. Crucial funding was provided by Cancer Research UK and AstraZeneca, with additional support from the NIHR Cambridge Biomedical Research Centre, the Cancer Research UK Cambridge Centre, and Addenbrooke’s Charitable Trust (ACT). This multi-faceted support highlights the collective commitment within the UK’s scientific and healthcare communities to advancing cancer treatment and ultimately, saving lives.
